21st Nov 2007 08:19
Stem Cell Sciences plc21 November 2007 Press Release STEM CELL SCIENCES APPOINTS DR ALASTAIR RIDDELL AS EXECUTIVE DIRECTOR 21 November 2007 Stem Cell Sciences plc (SCS, AIM:STEM, ASX: STC) the global biotechnologycompany focused on the commercialisation of stem cells and stem celltechnologies in research and cell-based therapies, announces today that DrAlastair James Riddell (58), CEO of SCS, has been appointed as an ExecutiveDirector with immediate effect. Dr Riddell is currently a Non-Executive Director of Sareum Holdings plc, aspecialist structure-based drug discovery company, and is an active Board memberof the BioIndustry Association, a position he has held from 2000 to 2006 andrecently re-elected to serve for the 2008 term. He was previously Non-ExecutiveChairman of Surface Therapeutics Limited overseeing the company's acquisition bySerentis Inc. in September 2007. Dr Riddell was formerly a director at ParadigmTherapeutics Limited, Pharmagene plc, Pharmagene Laboratories Trustees Limitedand Pharmagene Therapeutics Limited. The Company confirms there is no other information required to be disclosedunder Schedule 2 paragraph (g) of the AIM Rules. - Ends - For further information, please contact: Stem Cell Sciences plc (United Kingdom) +44 131 6629829Alastair Riddell, CEO Halsin Partners (United Kingdom) +44 20 70845955Michael Sinclair, Director Talk Biotech (Australia) +61 4 2220 6036Fay Weston Stem Cell Sciences llc (USA) +1 678 641 4029David Dodd, Chairman of SCS plc Notes to Editors About Stem Cell Sciences plc Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,established in Melbourne, Australia in 1994, providing products in theburgeoning stem cell research and drug discovery markets, in addition to thetargeted development of cell-based therapies for neurodegenerative disease andinjury. The Company has established a leading intellectual property (IP) and technologyportfolio that enables the commercial application of stem cells in drugdiscovery, providing the Company with early-stage revenue streams and technologydevelopment for at scale cell production of SCS cell-based therapeutics. SCSprincipal focus is in neurological disease. Revenues in the neurotech market,including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110billion Neurotech Insights, Volume 2/3 April 30 2006. SCS has operations in the UK, US and Australia, and is affiliated with academiccentres of excellence, including the Institute of Stem Cell Research (ISCR),Edinburgh, UK, RIKEN Centre for Development Biology, Kobe, Japan and theAustralian Stem Cell Centre, Melbourne, Australia. For further information on the company please visit: www.stemcellsciences.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SThree